JJ

Active Director Director DIN 05264599
DIN 05264599 First appointment Mar 2012 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Mar 2012
Shareholding value •••• Premium profile

About Jacob Job

Data last updated:

Jacob Job is a Director at Lycus Pharma Private Limited (since 2012). The company operates in Pharma. Lycus Pharma Private Limited reported revenue of ₹3.00 Cr (FY 2022).

DIN 05264599
Primary Designation Director
Industry Pharma
First Appointment 30 Mar 2012
Oldest Company Age 17 yrs
Largest company Lycus Pharma Private Limited · ₹3.00 Cr (FY 2022)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Lycus Pharma Private Limited U52311KL2009PTC024412
Director30 Mar 20122009₹3.00 Cr (FY 2022)Active

Board colleagues of Jacob Job

Directorship timeline

Open interactive timeline →
Lycus Pharma Private Limited
Premium access

Shareholding and investment profile for Jacob Job

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Jacob Job

Jacob Job currently holds 1 directorship: Lycus Pharma Private Limited (Director, since 30 Mar 2012, revenue ₹3.00 Cr (FY 2022)).

Jacob Job was first appointed on 30 Mar 2012 as Director at Lycus Pharma Private Limited.

The current boards of Jacob Job's companies include Jayan Padmanabhan (Lycus Pharma Private Limited), Jose Joseph (Lycus Pharma Private Limited), Lathish Pulickaparambil Narayanan Nair (Lycus Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available